Anti-inflammatory metabolite derived from omega-3-type fatty acid

Patent metadata

Field	Value
Publication number	US-9238634-B2
Application number	US-201113817079-A
Country	US
Kind code	B2
Filing date	Aug 4, 2011
Priority date	Aug 19, 2010
Publication date	Jan 19, 2016
Grant date	Jan 19, 2016

Abstract

The purpose is to provide a compound which can overcomes the disadvantages of conventional steroid drugs and NSAID. It is found that specific epoxy monohydroxy forms of eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid which are independently represented by formulae [chemical formula 1], [chemical formula 5] and the like have an inhibitory activity on neutrophils. This compound can inhibit the invasion of neutrophils into tissues and the activation of neutrophils which are observed in acute inflammations.

First claim

The invention claimed is:

1. A compound selected from the group consisting of:

hydrates of the compound, pharmaceutically acceptable salts of the compound, and hydrates of the salts; wherein,
when

is a single bond,
P 1 is hydrogen, alkyl, or hydroxy and
R 1 is hydrogen, or substituted or unsubstituted, branched or unbranched alkyl;
when

is a double bond, P 1 and R 1 are not present;
X is —C(O)OR 2 ;
R 2 is a hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl; and
double bonds of the compound may each be independently in either a cis or trans configuration.

2. The compound according to claim 1 , selected from the group consisting of:

or hydrates of the compound, pharmaceutically acceptable salts of the compound, and hydrates of the salts.

3. A neutrophil suppressant composition comprising a compound according to claim 1 , a hydrate of the compound, a pharmaceutically acceptable salt of the compound, or a hydrate of the salt.

4. A pharmaceutical composition comprising a compound according to claim 1 , a hydrate of the compound, a pharmaceutically acceptable salt of the compound, or a hydrate of the salt.

5. The compound according to claim 1 , which is:

or hydrates of the compound, pharmaceutically acceptable salts of the compound, and hydrates of the salts.

6. The compound according to claim 1 , which is:

or hydrates of the compound, pharmaceutically acceptable salts of the compound, and hydrates of the salts.

7. The compound according to claim 1 , which is:

or hydrates of the compound, pharmaceutically acceptable salts of the compound, and hydrates of the salts.

8. The compound according to claim 1 , which is:

or hydrates of the compound, pharmaceutically acceptable salts of the compound, and hydrates of the salts.

9. The compound according to claim 1 , which is:

or hydrates of the compound, pharmaceutically acceptable salts of the compound, and hydrates of the salts.

10. A neutrophil suppressant composition comprising a compound according to claim 2 , a hydrate of the compound, a pharmaceutically acceptable salt of the compound, or a hydrate of the salt.

11. A pharmaceutical composition comprising a compound according to claim 2 , a hydrate of the compound, a pharmaceutically acceptable salt of the compound, or a hydrate of the salt.

Assignees

• Arita Makoto
• Arai Hiroyuki
• Isobe Yosuke
• Kubota Tadafumi
• Univ Tokyo

Inventors

• Arita Makoto
• Arai Hiroyuki
• Isobe Yosuke
• Kubota Tadafumi

Classifications

• A61P5/24

  of the sex hormones · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title